Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis

  |  

Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are…

Physicians as Targets of Medical Workplace Violence

  |  

Tuesday, Jan. 20, a busy morning lay ahead for the staff of the cardiovascular surgery clinic. There were several new patients to see. No doubt, many of them were anxious to hear whether the skills of the surgeons they were going to meet could help them live another day. There were countless follow-up visits and…

First Biosimilar Drugs Approved in U.S., Canada

  |  

The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…

Case Report: Rheumatoid Arthritis and Degenerative Disk Disease

Patricia Frisch, PhD; Ronald R. Butendieck, MD; Andy Abril, MD; Peter M. McIntosh, MD; Salim M. Ghazi, MD; Elliot L. Dimberg, MD; Lynn F. Feldman, DO; David G. Lucas, MD; and Andrea Styron, MSR-PT  |  

Combination therapy includes abatacept for patient with erosive, chronic RA, underlying osteoarthritis and degenerative disk disease